Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1323495 in non-cystic fibrosis bronchiectasis
NCT04656275Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 1323495 in Non-cystic fibrosis bronchiectasis (NCFB) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Subjects With Drug-related Adverse Events up to 13 weeks. Started Mar 2021; status: terminated.
02
Drugs
BI 1323495
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT04656275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656275.